clinical trial · NCT07013851
Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer
Grupo Español de Investigación en Cáncer de Ovario·phase2·not yet recruiting·n = 25
MMRd/MSI-H Stage II-III Endometrial CancerDostarlimab
brief summary
The study for which participation is requested is a phase II clinical trial to assess the efficacy of dostarlimab as neoadjuvant therapy in patients with MMRd/MSI-H stage II-III endometrial cancer. The study is conducted in Spain with an estimated number of 25 patients for phase II. The main objective of this phase-II study is to evaluate the clinical complete response (cCR) after neoadjuvant therapy with dostarlimab.
started
Oct 1, 2025
primary completion
Mar 1, 2029
completion
Oct 1, 2029
last updated
Jun 10, 2025
official title
Phase II Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol